The progression of cardiometabolic risk to cardiovascular disease

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 4, 2007, Pages

  Rosin, Benjamin L ^a,b  

^a TORRANCE MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adipokines; Endocannabinoid CB1 receptor system; Metabolic syndrome; Visceral obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADIPSIN; CANNABINOID 1 RECEPTOR; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; ADIPONECTIN, HUMAN; ANTIOBESITY AGENT; AUTACOID; FATTY ACID; UNCLASSIFIED DRUG;

BLOOD CLOTTING DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; ENERGY METABOLISM; FATTY ACID METABOLISM; FIBRINOLYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; VASCULAR DISEASE; WEIGHT REDUCTION; BLOOD; BLOOD CLOTTING; DIET; DYSLIPIDEMIA; EXERCISE; LIFESTYLE; METABOLISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK FACTOR;

ADIPONECTIN; ANTI-OBESITY AGENTS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; DYSLIPIDEMIAS; EXERCISE; FATTY ACIDS; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LEPTIN; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINES; RISK FACTORS; WEIGHT LOSS;

EID: 35348888911     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005;51:931-938.
3. Forest C, Corval P, Lazdunski M. New developments in metabolic syndrome. Proceedings of the 1st Conference of the Paul Hamel Institute. Biochimie. 2005;87:1-132.
4. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol. 2005;5:122-128.
5. Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin Dermatol. 2004;22:289-295.
6. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003;Mar:10-17.
7. Grundy S. Contemporary Diagnosis and Management of the Metabolic Syndrome. Newton, PA: Handbooks in Health Care; 2005:18-24.
8. Anderwald C, Roden M. Adipotoxicity and the insulin resistance syndrome. Pediatr Endocrinol Rev. 2004;1:310-319.
9. Grundy SM, Mok HY, Zech L, et al. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest. 1979;63:1274-1283.
10. Carr MC, Hokanson JE, Zambon A, et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab. 2001;86:2831-2837.
11. Matsuda M, Shimomura I. Adipocytokines and metabolic syndrome - molecular mechanism and clinical implication [in Japanese], Nippon Rinsho. 2004;62:1085-1090.
12. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300.
13. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
14. Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004;59:305-331.
15. Flier JS. Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab. 1998;83:1407-1413.
16. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002;51:3176-3188.
17. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003;14:447-455.
18. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
19. Sobel BE. Coronary disease in type 1 diabetes: causal contiguity and clinical implications. Diabetes Care. 2003;26:1629-1630.
20. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002;3:85-101.
21. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc. 2001;60:341-347.
22. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807-825.
23. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270-278.
24. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499-1504.
25. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
26. Lindstrom J, Eriksson JG, Valle TT, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol. 2003;14(7 suppl 2):S108-S113.
27. Park HS, Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet Med. 2005;22:266-272.
28. Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis. 2001;11:195-204.
29. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323-341.
30. Despres JP, Golay A, Sjostrom L for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
31. Van Gaal LF, Rissanen AM, Scheen AJ, et al for RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397. Erratum in: Lancet. 2005;366:370.
32. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775. Erratum in: JAMA. 2006;295:1252.